Microbot Medical Expands At-The-Market Equity Offering Program

Microbot Medical ( (MBOT) ) has issued an announcement.

Microbot Medical Inc. has amended and is utilizing its existing at-the-market equity offering program with H.C. Wainwright & Co., allowing it to sell up to $39,230,691 of its common stock from time to time. The shares may be sold through various market mechanisms on or through the Nasdaq Capital Market or to market makers and in negotiated transactions, under a prospectus supplement to its effective shelf registration statement, providing the company with flexible access to equity capital as market conditions permit.

The company will file a prospectus supplement with the U.S. Securities and Exchange Commission covering the offer and sale of these at-the-market shares. This framework formalizes Microbot Medical’s ability to raise funds opportunistically in the public markets, which could support ongoing corporate and product development activities while potentially diluting existing shareholders depending on the volume and timing of issuances.

The most recent analyst rating on (MBOT) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.

More about Microbot Medical

Microbot Medical Inc. is a medical technology company whose common stock trades on the Nasdaq Capital Market. The company accesses capital markets to support its operations by issuing common shares under shelf registration statements and at-the-market equity offering programs.

Average Trading Volume: 1,994,152

Technical Sentiment Signal: Hold

Current Market Cap: $166.6M

See more insights into MBOT stock on TipRanks’ Stock Analysis page.